Research context (RUO): A peptide stack is a combination of two or more peptides within one research protocol. All blends mentioned on this page are supplied exclusively for in-vitro laboratory research and are not intended for human or animal use.
Peptide stacks & combinations: research into blends
Peptide stacks — fixed combinations of several peptides in one vial or protocol — are among the most studied topics in contemporary peptide research. Instead of isolating a single molecule, researchers bring together several peptides that each act on a different mechanism, with the hypothesis that the combined action is greater or broader than that of the individual components. On this page we explain what a “stack” or “blend” exactly is, why researchers combine, and we describe the blends that Peplife carries. Important upfront: every combination is a research protocol, not a use recommendation.
What is a peptide stack or blend?
The terms “stack” and “blend” are used interchangeably in the research field, but there is a nuance. A blend usually refers to several peptides that have already been physically combined in one vial — so after reconstitution the solution contains all components in a fixed ratio. A stack describes more broadly the combining of peptides within one research setup, whether they are in the same vial or handled as separate preparations. In both cases the starting point is the same: researchers want to study how different peptides relate to each other when they are introduced together into a model system.
The ratios in a blend are not arbitrary. They are determined by the molecular properties of the components — think of solubility, stability and the relative concentrations at which the peptides were studied in earlier individual studies. That is why the exact composition of each blend can always be found on the relevant product page.
Why do researchers combine peptides?
The rationale behind peptide stacks comes down to one central idea: complementary mechanisms. Many peptides act on different receptors or signalling pathways. When two peptides act via independent pathways that converge on the same endpoint, the hypothesis is that the combined effect may be greater than the sum of the parts. Researchers then speak of possible synergy.
A classic example from growth hormone research illustrates this. A GHRH analogue (which stimulates the pituitary via GHRH receptors) and a ghrelin mimetic (which acts via the GHSR-1a receptor) activate two different pathways that both lead to the release of growth hormone. In a 2009 study, Veldhuis and Bowers reported that the simultaneous activation of both pathways elicited a greater response in subjects than each pathway separately — the pathways reinforced each other rather than simply adding up. Observations like this form the scientific basis for why combinations are studied at all.
Other reasons to combine include bundling different research areas into one protocol (for example tissue repair and angiogenesis) and practically simplifying a study setup. At the same time, combining brings extra complexity: interactions between components are by no means always predictable, and for most specific combinations there are no direct comparative studies yet. The rationale therefore often leans on the pharmacology of the individual components.
The blends that Peplife carries
Below are the main peptide stacks in the range, each with the research context in which the combination is relevant. All descriptions are attributed to research, not to use.
- GLOW: combines BPC-157, TB-500 and GHK-Cu. These three peptides are each studied separately for tissue repair, angiogenesis and collagen/skin models respectively. In the blend they are brought together within regenerative research, where the hypothesis is that repair-focused and skin-focused mechanisms complement each other.
- KLOW: builds on GLOW by adding KPV to GHK-Cu, BPC-157 and TB-500. KPV is studied in preclinical models for inflammation-related processes, which gives KLOW, as a four-part blend, a broader research profile than GLOW.
- Wolverine (BPC-157 + TB-500): the best-known recovery blend, built from BPC-157 and TB-500. Both peptides are studied in animal models for tissue repair; researchers combine them because BPC-157 is mainly studied for local repair and angiogenesis processes, while TB-500 (a thymosin beta-4 fragment) is associated with cell migration in models. See also our comparison BPC-157 vs TB-500.
- CagriSema: a combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist). This combination has been intensively studied in clinical trials: in the REDEFINE 1 study, published in 2025, researchers reported an average body weight reduction of over 20% compared with placebo in adults with overweight or obesity. The two molecules act on different metabolic pathways, which makes the blend a much-studied example of complementary action.
- GH STACK: a blend centred around the growth hormone axis, combining peptides from the GHRH and GHRP families. The research rationale follows the principle described above of two converging routes to growth hormone release. More background in our pillar on growth hormone peptides.
- RETA TOWER: a metabolic stack centred around retatrutide, a peptide that targets multiple metabolic receptors in clinical research. The stack bundles metabolism-focused research into a single protocol.
- RECOVERY STACK: a recovery-oriented combination bringing together peptides from tissue-repair research, in line with the logic behind the Wolverine blend.
- CJC-1295 + Ipamorelin: perhaps the textbook example of a complementary blend. CJC-1295 is a GHRH analogue, Ipamorelin a selective ghrelin mimetic. In research models they activate two different receptor systems (GHRH receptor and GHSR-1a) that both result in growth hormone release. Note: for this specific combination there are as yet no published comparative human trials — the rationale comes from the pharmacology of the individual components and related GHRH-plus-GHRP studies.
Peptide stacks in laboratory research: handling & dissolving
Like individual peptides, blends are supplied as freeze-dried powder and must be reconstituted for research. Because a blend contains several components in one vial, a consistent solvent and ratio are important for reproducible results. The general principles are described in our pillars on reconstituting peptides and which liquid to use. This information is aimed exclusively at handling in a laboratory environment.
Quality & purity
For blends, analytical control is extra important, because several components have to be present in the correct ratio. Every relevant batch is independently HPLC-tested by an external laboratory; the certificate of analysis (CoA) is publicly verifiable per batch. This way, for each stack it is verifiable which peptides and which purity are actually in the vial. Read also why we rejected a batch.
Frequently asked questions about peptide stacks
What is the difference between a peptide stack and a blend?
A blend is usually one vial in which several peptides have already been physically combined in a fixed ratio. A stack is the broader term for combining peptides within one research protocol. In practice, both terms are often used interchangeably.
Why are peptides combined in research?
Because different peptides act on different receptors or signalling pathways. Researchers combine them to study whether complementary mechanisms together produce a greater or broader effect than the individual components — the idea of possible synergy.
Are peptide stacks better than single peptides?
That is precisely what research tries to establish; it is not a given. For some combinations, such as CagriSema, extensive clinical data exist. For many other combinations, the rationale leans on the pharmacology of the individual peptides and direct comparative studies are still lacking.
What is in the GLOW and KLOW blends?
GLOW combines BPC-157, TB-500 and GHK-Cu. KLOW adds KPV to it and therefore contains four peptides. The exact ratios are on the relevant product pages and on the accompanying CoA.
Why are CJC-1295 and Ipamorelin studied together?
Because they activate two different pathways that both lead to growth hormone release: CJC-1295 as a GHRH analogue and Ipamorelin as a ghrelin mimetic. In research models, the hypothesis is that simultaneous activation produces a greater response than each pathway separately.
May these blends be used?
No. All peptide stacks are supplied exclusively for in-vitro laboratory research. They are not intended for human or animal use and not approved as a drug.
Read more & research at Peplife
- Research GLOW peptide blend at Peplife
- Research CagriSema at Peplife
- Research CJC-1295 + Ipamorelin blend
- View all stacks & bundles
- View all peptide blends
- BPC-157 vs TB-500: the differences in research
- Growth-hormone peptides: the research
Sources: REDEFINE 1 — Cagrilintide-Semaglutide (NEJM/PubMed, 2025) · Cagrilintide + Semaglutide: systematic review & meta-analysis (PMC) · CJC-1295 + Ipamorelin: GHRH-plus-ghrelin mechanism overview
Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.
All peptide stacks HPLC-tested by an external laboratory, with CoA per batch and discreet EU shipping.